• 1.

    Farouk SS , Rein JL . The many faces of calcineurin inhibitor toxicity—What the FK? Adv Chronic Kidney Dis 2020; 27:5666. doi: 10.1053/j.ackd.2019.08.006

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Vincenti F , et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016; 374:333343. doi: 10.1056/NEJMoa1506027. Erratum in: N Engl J Med 2016; 374:698. doi: 10.1056/NEJMx160003

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Adams AB , et al. Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function. Am J Transplant 2017; 17:29222936. doi: 10.1111/ajt.14353

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Cicora F , et al. Belatacept-based, ATG-Fresenius-induction regimen for kidney transplant recipients: A proof-of-concept study. Transpl Immunol 2015; 32:3539. doi: 10.1016/j.trim.2014.10.002

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Kumar D , et al. Belatacept as an alternative to calcineurin inhibitors in patients with solid organ transplants. Front Med (Lausanne) 2017; 4:60. doi: 10.3389/fmed.2017.00060

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Ferguson R , et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11:6676. doi: 10.1111/j.1600-6143.2010.03338.x

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Radbruch A , et al. Competence and competition: The challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6:741750. doi: 10.1038/nri1886

  • 8.

    Ajaz B , et al. Plasma cell CD20 expression: Primary aberrant expression or receptor up-regulation. Leuk Lymphoma 2014; 55:444446. doi: 10.3109/10428194.2013.802782

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Lee J , et al. The effect of bortezomib on antibody-mediated rejection after kidney transplantation. Yonsei Med J 2015; 56:16381642. doi: 10.3349/ymj.2015.56.6.1638

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Woodle ES , et al. Plasma cell targeting to prevent antibody-mediated rejection. Am J Transplant 2020; 20:3341. doi: 10.1111/ajt.15889

Novel Therapeutics in Kidney Transplantation Belatacept, Bortezomib, Battlestar Galactica

  • 1 Samira S. Farouk, MD, MSCR, FASN, is affiliated with the Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Restricted access

"Continue FK, MMF, pred."

Most nephrologists learn early in their training that the most common immunosuppressant regimen for patients with a kidney transplant consists of a calcineurin inhibitor (CNI), mycophenolic acid (usually mycophenolate mofetil [MMF]), with or without some corticosteroid. Let’s take a quick look at two emerging outside-the-box immunosuppression tools.

The new kid on the block

CNIs have long been a thorn in kidney transplantation’s side—with a laundry list of adverse effects ranging from tremors to electrolyte disturbances to paradoxical nephrotoxicity (1). One newer drug that has provided a CNI-free option in some patients is belatacept (approved

Save